Eme Red Hospitalaria

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Type 2 diabetes5 trials
• Obesity4 trials
• Bladder cancer1 trial
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Lupus (SLE)1 trial
• Obstructive sleep apnoea1 trial
• Osteoarthritis1 trial
• Peripheral artery disease1 trial
• Stroke1 trial

Phase

• Phase 38 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Completed4 trials
• Withdrawn1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Novo Nordisk A/S2 trials
• Janssen Research & Development, LLC1 trial
• Zenas BioPharma (USA), LLC1 trial

Running trials

• Active, not recruiting

  A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

  NCT06559163· Phase 2· Zenas BioPharma (USA), LLC· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

Closed trials

• Completed

  Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

  NCT06354660· Phase 3· Eli Lilly and Company· Source

• Withdrawn

  Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

  NCT06083675· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

  NCT05929066· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source